Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by Privium Fund Management B.V.

Privium Fund Management B.V. lifted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 45.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,250 shares of the company's stock after acquiring an additional 2,900 shares during the period. Krystal Biotech makes up approximately 0.3% of Privium Fund Management B.V.'s portfolio, making the stock its 29th largest position. Privium Fund Management B.V.'s holdings in Krystal Biotech were worth $1,449,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech in the third quarter worth approximately $40,000. KBC Group NV raised its stake in Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company's stock valued at $117,000 after purchasing an additional 132 shares during the period. Avanza Fonder AB bought a new position in shares of Krystal Biotech during the 4th quarter valued at about $119,000. Blue Trust Inc. grew its holdings in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after buying an additional 433 shares in the last quarter. Finally, US Bancorp DE raised its stake in Krystal Biotech by 8.7% during the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Insider Transactions at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Friday, February 28th. Finally, Chardan Capital upped their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a report on Thursday, February 20th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech has an average rating of "Buy" and an average price target of $220.00.

Krystal Biotech Stock Down 0.8 %

Krystal Biotech stock traded down $1.46 during trading on Friday, reaching $187.15. The stock had a trading volume of 328,246 shares, compared to its average volume of 284,188. The stock has a market cap of $5.39 billion, a PE ratio of 62.59 and a beta of 0.87. The business has a 50 day moving average price of $166.67 and a 200 day moving average price of $173.65. Krystal Biotech, Inc. has a 52-week low of $141.72 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.29 by $0.23. The business had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business's quarterly revenue was up 116.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.30 EPS. On average, equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).